Director/PDMR Shareholding

RNS Number : 7302M

Yourgene Health PLC

13 January 2023

 

Yourgene Health plc

("Yourgene" or the "Company")

Director/PDMR Shareholding

Manchester, UK - 13 January 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified on 12 January 2023 that Bill Chang, Chief Entrepreneur of the Company, purchased 5,000,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") on 12 January 2023 at an average price of 0.344p per share.

Following the purchase, Bill Chang is interested in 289,000,142¹ Ordinary Shares, representing approximately 9.10 per cent. of the Company's issued share capital.

¹ 280,000,142 Ordinary Shares are held by Changsform Innovations Pte Ltd, Bill Chang is a company director and beneficial owner of Changsform Innovations Pte Ltd.

Furthermore, the Company was notified on 13 January 2023 that Barry Hextall, Chief Financial Officer of the Company, purchased 2,500,000 Ordinary Shares on 13 January 2023 at an average price of 0.3678p per share.

Following the purchase, Barry Hextall is interested in 6,500,000 Ordinary Shares, representing approximately 0.20 per cent. of the Company's issued share capital.  

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.

Yourgene Health plc Lyn Rees, Chief Executive Officer	Tel: [phone] [e-mail]
Barry Hextall, Chief Financial Officer
Joanne Cross, Director of Marketing
Cairn Financial Advisers LLP (NOMAD)	Tel: [phone]
Liam Murray / Ludovico Lazzaretti
Singer Capital Markets (Corporate Broker)	Tel: [phone]
Aubrey Powell / Tom Salvesen / George Tzimas
Walbrook PR Ltd (Media and Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus / Lianne Applegarth	Mob: [phone] / Mob: [phone]

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises integrated genomic technologies and services enabling genomic medicine in over 60 territories. The group works in partnership with global leaders in DNA technology to advance diagnostic science and support precision medicine.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and an extension into the precision medicine space with DPYD genotyping.

Yourgene has a range of innovative DNA sample preparation platforms, and launched Yourgene Genomic Services in 2020, which has enabled Yourgene to offer a global laboratory service network equipped to provide high quality genetic testing and bioinformatics solutions and serve as a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr Bill Chang
2	Reason for the notification
a)	Position/status	Chief Entrepreneur
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Yourgene Health plc
b)	LEI	213800UUIT8BZE7QEH33
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 0.1p each
	Identification code	ISIN: GB00BN31ZD89
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			0.349p	1,000,000
			0.349p	1,000,000
			0.34p	1,000,000
			0.34p	900,000
			0.34p	100,000
			0.34p	900,000
			0.34p	100,000
d)	Aggregated information
	- Aggregated volume	5,000,000
	- Price	0.344p
e)	Date of the transaction	12 January 2023
f)	Place of the transaction	London

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Barry Hextall
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Yourgene Health plc
b)	LEI	213800UUIT8BZE7QEH33
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 0.1p each
	Identification code	ISIN: GB00BN31ZD89
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			0.3678p	2,500,000
d)	Aggregated information	N/A
	- Aggregated volume
	- Price
e)	Date of the transaction	13 January 2023
f)	Place of the transaction	UK

 

END

 

 

DSHQXLFFXFLLBBE